AX9 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained positive operating and free cash flow (~$60M TTM) materially improves Akebia’s ability to fund operations, advance trials and commercial rollout without immediate financing. This cash conversion supports runway, reduces near-term dilution risk and underpins multi-quarter execution of Vafseo and pipeline plans.
Positive VOICE Interim ResultsAn interim VOICE readout showing non-inferiority and statistical superiority with fewer hospitalizations strengthens Vafseo’s clinical and safety profile in dialysis patients. A robust outcome that led to early stopping improves payer and provider confidence, supporting durable prescribing and market access over coming quarters.
Rapid Vafseo AdoptionQuarterly revenue growth, tripling prescriber engagement and ~60% QoQ patient growth indicate accelerating commercial traction. Broadening adoption across dialysis providers and high observed-dosing adherence suggest the product can scale, supporting sustained revenue expansion as more clinics shift to 3x weekly dosing.
Bears Say
Auryxia Revenue ErosionMaterial declines in Auryxia revenue from authorized and new generics reduce a legacy cash stream and concentrate commercial reliance on Vafseo. Persistent generic pressure can compress overall revenue and margins, requiring higher Vafseo uptake or external funding to offset recurring revenue loss over multiple quarters.
Profitability Volatility & ChargesA swing to net loss amid inventory write-downs and rising R&D/SG&A highlights earnings volatility and operational risk. Ongoing restructuring, higher trial costs and potential additional write-downs can pressure cash and margins, forcing trade-offs between funding pipelines and preserving commercial investment.
Balance Sheet Still ConstrainedLower debt improves flexibility but small equity and negative ROE limit capacity to absorb setbacks or fund large-scale commercialization without dilution. Combined with approved share-authority increases, the structural weakness in equity base raises the likelihood of future equity financing if cash generation or commercialization stalls.
Akebia Therapeutics News
AX9 FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Akebia Therapeutics’s market cap?
Akebia Therapeutics’s market cap is CHF286.01M.
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 3 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on May 07, 2026. The company reported -CHF0.024 earnings per share for the quarter, missing the consensus estimate of -CHF0.023 by -CHF0.002.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Akebia Therapeutics have?
Currently, no data Available
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of -CHF0.024 in its last earnings report, missing expectations of -CHF0.023. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Currently, no hedge funds are holding shares in CH:AX9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Akebia Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF4.85 (― Upside)
CHF4.85 (― Upside)
Blogger Sentiment
Bullish
CH:AX9 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth CHF50.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.87%
Trailing 12-Months
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
AX9 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights strong commercial momentum for Vafseo (32% revenue growth, ~60% patient growth quarter-over-quarter, higher prescriber engagement and improved adherence under observed dosing) and meaningful pipeline progress with supportive clinical data and upcoming readouts. However, legacy product Auryxia faces notable generic-driven revenue decline (≈-17%), the company swung to a net loss in the quarter, experienced sizable inventory write-downs and higher operating expenses, and cash declined q/q. While the launch and clinical developments are encouraging and provide a clear growth narrative, the near-term financial headwinds and competitive/enrollment risks temper the outlook.View all CH:AX9 earnings summariesAX9 Stock 12 Month Forecast
Average Price Target
―Oruka Therapeutics
―
Theravance Biopharma
―
Vir Biotechnology
―
ProKidney
―
ArriVent BioPharma, Inc.
―